A One-Time Gene-Editing Treatment for High Cholesterol Shows Strong Results at 1 Year: What the New CTX310 Data Mean

Table of Contents

• Key Points
• Why This Research Matters
• How the Study Was Designed
• How CTX310 Works: The Science Explained
• Safety at 1 Year: What the Researchers Found
• Effectiveness at 1 Year: Detailed Results
• Other Gene-Editing Approaches for Lipid Disorders
• Clinical Implications: What This Could Mean for Patients
• Study Limitations
• What Happens Next
• Frequently Asked Questions
• Source Information

Key Points

• A single infusion of gene-editing therapy CTX310 lowered LDL cholesterol by 52.5% and triglycerides by 47.8% at 1 year in 4 patients at the highest dose.
• CTX310 disables the ANGPTL3 gene in the liver, mimicking naturally occurring genetic mutations that protect people from heart disease.
• In this 15-patient early trial, no dose-limiting toxic effects and no new safety concerns appeared over the first year of follow-up.
• The treatment is experimental and only available in clinical trials; patients should continue prescribed lipid-lowering medications until doctors advise otherwise.
• One-year results are encouraging but not definitive—larger studies are needed to confirm durability, safety, and which patient subgroups benefit most.

Why This Research Matters

Heart attacks and strokes are often driven by atherosclerosis — the buildup of cholesterol-filled plaque inside arteries. Many patients lower their risk with daily statin pills and other medications. Yet some people cannot reach healthy cholesterol targets, and daily lifelong treatment is a burden for many others.

Gene editing offers a radical alternative. The idea is simple: instead of taking a drug every day for decades, a patient would receive one treatment that permanently disables a specific gene in the liver, changing how the body handles cholesterol from that point forward.

The new research focuses on CTX310, an experimental therapy that edits the gene for ANGPTL3 (angiopoietin-like protein 3). ANGPTL3 is a protein made in the liver that normally acts as a brake on the enzymes that clear fats from the blood. When that brake is removed — by a natural genetic variation or by gene editing — the liver produces less ANGPTL3, and levels of harmful fats in the bloodstream drop.

People born with natural loss-of-function mutations in the ANGPTL3 gene have lower lipid levels and a reduced risk of atherosclerotic cardiovascular disease, meaning they are protected from the artery-clogging process that causes heart attacks and strokes. By recreating that same type of mutation with CRISPR-Cas9 gene editing, CTX310 aims to deliver a similar lifelong benefit as a single treatment.

This article is based on a letter published in the New England Journal of Medicine that provides the 1-year follow-up results for all patients treated with CTX310 in an early clinical trial.

How the Study Was Designed

The study was a phase 1a, open-label, multicenter trial, meaning it was the first stage of human testing, everyone involved knew which treatment was being given, and patients were treated at multiple sites in Australia and New Zealand (registry number ACTRN12623000809639).

From May 2024 through August 2025, researchers enrolled 15 adults with lipid disorders that were not adequately controlled. The patients fell into three groups:

• Uncontrolled hypercholesterolemia (very high levels of cholesterol)
• Moderate or severe hypertriglyceridemia (very high levels of triglycerides, a type of fat in the blood)
• Mixed dyslipidemia (both cholesterol and triglycerides elevated)

Each participant received one infusion of CTX310 at one of five dose levels: 0.1, 0.3, 0.6, 0.7, or 0.8 mg per kilogram of body weight. The number of patients per dose group was small — for example, 2 patients in the lowest-dose group, 3 in the middle groups, and 4 in the highest-dose (0.8 mg/kg) group, according to the data shown in the trial figures.

The primary end point — the main outcome the study was designed to measure — was safety, specifically adverse events (unwanted medical effects), including dose-limiting toxic effects (side effects severe enough to prevent giving a higher dose). Lipid levels and ANGPTL3 levels were measured as secondary markers of effectiveness, following each patient from before treatment through 1 year afterward.

The results reported here update an earlier publication (Laffin et al., N Engl J Med 2025;393:2119-30) that described the early safety and efficacy of CTX310. This new letter adds a full 1-year follow-up for every trial participant.

How CTX310 Works: The Science Explained

CTX310 is a lipid nanoparticle-encapsulated CRISPR-Cas9 messenger RNA and guide RNA. In plain language, it is a tiny fat bubble (nanoparticle) that carries two key ingredients into liver cells (hepatocytes):

1. The genetic instructions (messenger RNA, or mRNA) for making the Cas9 enzyme, and
2. A guide RNA that directs Cas9 to the exact spot in the ANGPTL3 gene to be cut.

Once inside the liver cell, the Cas9 enzyme makes a precise cut in the DNA. The cell repairs that cut using a process that often introduces a small error, producing a loss-of-function mutation — a genetic change that inactivates the ANGPTL3 gene. Because liver cells live a long time and the edit is permanent in those cells, the effect is intended to last many years, potentially a lifetime.

CRISPR-Cas9 stands for clustered regularly interspaced short palindromic repeats–Cas9 endonuclease — a naturally occurring bacterial system, adapted for medical use, that acts like molecular scissors guided to a specific DNA sequence.

This approach mimics naturally occurring human mutations in the ANGPTL3 gene that are known to be protective against heart disease. People with those natural variants live healthy lives with lower lipid levels, giving researchers confidence that a deliberate version of the same change may also be safe and beneficial.

Safety at 1 Year: What the Researchers Found

The headline finding for safety is straightforward: no dose-limiting toxic effects occurred, and no new safety concerns appeared after the first year of follow-up.

Two serious adverse events were reported earlier in the trial. The investigators considered both to be unrelated to CTX310, and one event was later determined to be a preexisting condition. After the initial publication, the researchers report that there were no new serious adverse events and no adverse events of special interest (a category of side effects singled out for close monitoring, such as allergic reactions or liver injury).

One participant did have a transient elevation in aminotransferase values (liver enzymes, a sign of possible liver irritation) shortly after treatment. This was already known from the earlier report. Importantly, no other elevations in liver-function measures occurred for the remainder of the trial, meaning CTX310 did not appear to cause lasting liver damage in this small group.

Full details of all adverse events throughout the trial were provided in Table S1 of the Supplementary Appendix that accompanies the published letter. It is worth emphasizing that safety results from a 15-patient trial are reassuring but not definitive — rare side effects can only be detected in much larger studies.

Effectiveness at 1 Year: Detailed Results

The key efficacy finding is that the reductions in ANGPTL3 and harmful blood fats were large and, importantly, were sustained at 1 year after a single infusion. This durability over time is the new information this letter adds.

Among the 4 participants who received the highest dose (0.8 mg per kilogram), the mean percent changes at 1 year were:

• ANGPTL3 (the target protein): down by 78.6% (range across patients, −89.0% to −63.1%)
• LDL cholesterol (the "bad" cholesterol that clogs arteries): down by 52.5% (range, −84.2% to −24.4%)
• Triglycerides (blood fats linked to heart and pancreas risk): down by 47.8% (range, −77.6% to −14.7%)
• Non-HDL cholesterol (all cholesterol carried in artery-clogging particles): down by 52.0% (range, −79.4% to −25.2%)
• HDL cholesterol (the "good" cholesterol): down by 23.5% (range, −44.9% to 0.0%)
• Apolipoprotein B (apoB, the number of artery-clogging particles): down by 37.2% (range, −61.2% to −12.9%)
• Triglyceride-rich lipoprotein cholesterol (TRL cholesterol, another harmful particle type): down by 71.7% (range, −87.8% to −56.1%)

The change in HDL cholesterol is worth explaining. A decline in "good" cholesterol might sound bad, but many specialists see it as an expected and generally acceptable effect of treatments that dramatically lower the triglyceride-rich particles, because the same metabolic pathway handles both. The trial did not report any harm associated with this change.

To make the scale of these reductions easier to picture: a 52.5% average drop in LDL cholesterol is in the same range as what many patients achieve with the most potent daily statins or with injectable PCSK9 inhibitors — except here it occurred after one infusion, without ongoing medication.

A few additional points from the results:

• The changes in individual participants at the highest dose varied widely — LDL reductions ranged from 24.4% to 84.2% depending on the person — which shows that individual responses differ.
• Changes in ANGPTL3 levels and lipid biomarkers were shown in Table S2 of the Supplementary Appendix; the percent changes from baseline over time are shown in figures in the letter (Figure 1 and Figure S1).
• The trial figures plot the mean percent change from baseline for ANGPTL3, LDL cholesterol, triglycerides, and non-HDL cholesterol at each dose level, with standard-error bars showing statistical spread. For the highest three doses, an inset graph in the triglyceride panel displays the same data on an expanded axis, making the sustained pattern easier to see.
• Details about how representative the trial population was compared with the broader patient population are provided in Table S3.

Because no p-values were reported in this letter, the results are best interpreted as descriptive evidence of effect size and durability, rather than as formal proof. The wide ranges remind us that this is a small, early-phase study.

Other Gene-Editing Approaches for Lipid Disorders

CTX310 is not the only gene-editing strategy in development for lipid disorders. The letter's authors point out that other investigators are testing a different type of gene editing — in vivo base editing — which makes a single-letter change in DNA rather than a double-stranded cut. These programs target a different gene: PCSK9 (proprotein convertase subtilisin–kexin type 9), a protein that regulates how many LDL receptors the liver makes.

The letter cites two notable examples:

• A phase 1 trial of in vivo base editing for heterozygous familial hypercholesterolemia, an inherited condition causing extremely high cholesterol from birth (Wan et al., Nature Medicine 2026;32:1045-51).
• A trial of a base-editing therapy called VERVE-102, which targets PCSK9 to treat hypercholesterolemia (Vafai et al., N Engl J Med 2026;395:648-59).

The letter also references a 2026 American College of Cardiology scientific statement on gene-editing therapy in cardiovascular disease, reflecting how quickly this field is moving and how seriously mainstream cardiology groups are taking it.

For patients, this competitive pipeline is good news: several approaches and target genes are being explored, increasing the odds that at least one will prove safe, durable, and beneficial in larger trials.

Clinical Implications: What This Could Mean for Patients

The authors state that CTX310 "was associated with few adverse events and produced sustained changes in the levels of ANGPTL3 and atherogenic lipoproteins at 1 year, further supporting its potential as a one-time treatment."

Put simply, this means a patient might one day receive a single infusion that permanently lowers their LDL cholesterol by roughly half or more and their triglycerides by a similar amount, with no need for daily or monthly medication. For patients with severe lipid disorders who cannot tolerate statins or who never reach target levels despite multiple drugs, that would be a transformative option.

The timing of the effect is particularly relevant. Changes in lipid biomarkers after CTX310 may vary according to the type of lipid disorder a patient has. The reductions appear to be reached within the first weeks to months after treatment, and the key message of this report is that they persist at least to the 12-month mark.

But durable gene edits also raise the stakes: an effect that lasts is an advantage, yet doctors will want to confirm over many more years that permanent lowering of ANGPTL3 is not linked to any late-appearing problems. The liver is central to countless body functions, so long-term monitoring of liver health and other metabolic effects will be essential before this therapy could be considered for widespread use.

Study Limitations

This letter is encouraging, but it is important to understand what it does not prove.

• Very small sample size. Only 15 adults were treated in this phase 1a trial, and the strongest efficacy numbers come from just 4 patients at the highest dose. A single patient's unusually large or small response can skew the averages.
• No control group. The trial was open-label and single-group. There was no comparison group receiving placebo or standard care, so we cannot separate the treatment effect from natural fluctuations or the placebo effect using this design alone.
• Limited follow-up window. One year proves durability so far, but not permanence. Whether ANGPTL3 levels remain suppressed at 5 or 10 years needs continued observation.
• Descriptive statistics only. The letter reports mean percent changes and ranges without p-values, so the findings are descriptive rather than hypothesis-proving.
• Selection of patients. The results may not apply equally to every lipid disorder. The authors explicitly note that biomarker changes may vary by lipid-disorder type, which is why the next phase of testing is organized by specific patient subgroups.
• Rare side effects cannot be excluded. A trial this size cannot detect uncommon safety problems, and the long-term consequences of permanently editing a metabolic gene are unknown.

What Happens Next: Recommendations and Ongoing Research

The research is continuing. The authors report that phase 1b of the trial is testing a fixed dose of 0.8 mg per kilogram of CTX310 in patients with refractory dyslipidemias — lipid disorders that have not responded adequately to existing therapies (ClinicalTrials.gov number, NCT07491172).

In this next phase, efficacy is being assessed in separate cohorts of patients with specific lipid disorders, an acknowledgment that a one-size-fits-all result may not apply across all patient types. These cohorts will give clearer answers about which patients benefit most.

For patients interested in gene-editing therapies for cholesterol, the practical recommendations remain:

1. Continue prescribed lipid-lowering medications until a treatment is approved and your doctor advises a change. Gene editing is still experimental and not available outside clinical trials.
2. Talk to a lipid specialist or cardiologist if your cholesterol or triglycerides remain uncontrolled despite standard therapy, because you may be a candidate for trials like this one.
3. Ask about clinical trial registries (such as ClinicalTrials.gov or the Australia New Zealand Clinical Trials Registry) to find current studies for which you might qualify.
4. Wait for longer-term data. The 1-year results are promising, but decisions about a permanent genetic change deserve the fullest possible evidence on safety and durability.

If phase 1b and subsequent larger trials confirm these findings, CTX310 could eventually represent one of the most significant advances in preventive cardiology in decades — a single treatment that durably addresses the root cause of high lipid levels rather than managing them day by day.

Frequently Asked Questions

What is CTX310 and how does it work?

CTX310 is an experimental gene-editing therapy given as a single infusion. It uses CRISPR-Cas9 to permanently disable the ANGPTL3 gene in liver cells. That gene normally helps block the breakdown of blood fats. Disabling it lowers levels of harmful lipids, including LDL cholesterol and triglycerides.

How effective was CTX310 after one year in the trial?

In a small early trial, 15 patients received one infusion. Among the 4 patients given the highest dose (0.8 mg/kg), mean reductions at 1 year were 78.6% for ANGPTL3 protein, 52.5% for LDL cholesterol, and 47.8% for triglycerides. Individual responses varied widely, and results are only descriptive.

Was CTX310 safe in the one-year study?

No dose-limiting toxic effects occurred, and no new safety concerns appeared during the first year. Two serious adverse events were reported earlier and were considered unrelated to CTX310. One patient had a temporary rise in liver enzymes. A 15-patient trial cannot detect rare side effects.

Who might be eligible for this kind of gene-editing therapy?

This trial enrolled adults with severe lipid disorders not adequately controlled by standard therapy, including very high cholesterol, very high triglycerides, or both. CTX310 is experimental and only available in clinical trials. Talk to a lipid specialist or cardiologist to see if you might qualify for similar trials.

How long does the effect of CTX310 last?

In the trial, reductions in LDL cholesterol, triglycerides, and ANGPTL3 were still present at 12 months after a single infusion. The edit is permanent in liver cells, but whether the effect lasts 5 or 10 years is as yet unknown and requires continued observation.

What are the main limitations of the CTX310 study?

The study included only 15 adults, and the strongest results came from 4 patients at the highest dose. It had no control group, followed patients for only one year, and reported descriptive statistics without p-values. Results may vary by lipid disorder type, and rare side effects cannot be excluded.

Should I get a second opinion before joining a CTX310 gene-editing trial for severe cholesterol that isn't controlled by statins?

For severe lipid disorders that remain uncontrolled on standard therapy, a second opinion can help determine whether experimental gene-editing treatment such as CTX310 is a reasonable next step. Current evidence comes from only 15 patients followed for one year; at the highest dose, ANGPTL3 fell by 78.6% and LDL cholesterol by 52.5%, but no control group was included and long-term safety is unknown. Existing lipid-lowering medications should be continued until a treatment is approved. A second opinion can confirm that all established options have been considered. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on peer-reviewed research published as a letter (Correspondence) in The New England Journal of Medicine.

• Original title: "Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310"
• Authors: Luke J. Laffin, M.D., Stephen J. Nicholls, M.B., B.S., Ph.D., Russell S. Scott, M.B., Ch.B., Ph.D., Peter M. Clifton, M.B., B.S., Ph.D., Renate Koops, M.D., Ashish Sarraju, M.D., Shweta Singh, Ph.D., Qiuqing Wang, M.S., Kathy Wolski, M.P.H., Huansheng Xu, Ph.D., Jen Nielsen, M.S., Naimish Patel, M.D., Jason M. Duran, M.D., Ph.D., and Steven E. Nissen, M.D. (Laffin and Nicholls contributed equally to the letter.)
• Journal: New England Journal of Medicine, published online August 28, 2026; DOI: 10.1056/NEJMc2609825
• Trial registrations: ACTRN12623000809639 (Australia New Zealand Clinical Trials Registry) and NCT07491172 (ClinicalTrials.gov)
• Funding and disclosures: The trial was supported by CRISPR Therapeutics, the company developing CTX310. Disclosure forms from the authors are available with the full text of the letter at NEJM.org. Investigators are affiliated with the Cleveland Clinic Coordinating Center for Clinical Research, Cleveland; the Victorian Heart Institute, Melbourne, Australia; New Zealand Clinical Research, Christchurch, New Zealand; Royal Adelaide Hospital, Adelaide, Australia; Aotearoa Clinical Trials, Auckland, New Zealand; and CRISPR Therapeutics, Boston.
• Prior related publication: Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. N Engl J Med 2025;393:2119-30.

This patient-friendly article is based on peer-reviewed research and is provided for educational purposes. It does not constitute medical advice. Anyone considering gene-editing therapy should discuss risks, benefits, and alternatives with their own physician.